What is Brookline Cap M’s Forecast for Lantheus Q3 Earnings?

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Brookline Cap M issued their Q3 2026 earnings per share (EPS) estimates for Lantheus in a research report issued to clients and investors on Wednesday, February 11th. Brookline Cap M analyst K. Dolliver expects that the medical equipment provider will post earnings per share of $1.18 for the quarter. The consensus estimate for Lantheus’ current full-year earnings is $6.01 per share. Brookline Cap M also issued estimates for Lantheus’ Q4 2026 earnings at $1.38 EPS.

LNTH has been the subject of several other research reports. Mizuho boosted their price target on Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Truist Financial boosted their target price on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average target price of $78.00.

Lantheus Stock Performance

Shares of LNTH stock opened at $69.38 on Friday. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $111.29. The stock’s 50-day moving average is $66.30 and its two-hundred day moving average is $59.56. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49. The firm has a market cap of $4.60 billion, a P/E ratio of 29.15 and a beta of -0.08.

Hedge Funds Weigh In On Lantheus

A number of institutional investors have recently modified their holdings of the company. Stanley Laman Group Ltd. boosted its holdings in Lantheus by 38.7% during the third quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after acquiring an additional 22,229 shares during the period. American Assets Inc. acquired a new position in shares of Lantheus during the 3rd quarter worth about $872,000. Campbell & CO Investment Adviser LLC bought a new stake in Lantheus during the 3rd quarter valued at approximately $2,184,000. Y Intercept Hong Kong Ltd acquired a new stake in Lantheus in the 3rd quarter valued at approximately $3,866,000. Finally, Fox Run Management L.L.C. bought a new position in Lantheus in the 2nd quarter worth approximately $654,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.